Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey
- PMID: 31116461
- PMCID: PMC6861871
- DOI: 10.1002/jca.21709
Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey
Abstract
Introduction: Anti-heparin/platelet factor 4 antibody immune complexes resulting from heparin-induced thrombocytopenia (HIT) are removed by therapeutic plasma exchange (TPE). We sought to define TPE in HIT practice patterns using an international survey.
Methods: A 31-item online survey was disseminated through the American Society for Apheresis. After institutional duplicate responses were eliminated, a descriptive analysis was performed.
Results: The survey was completed by 94 respondents from 78 institutions in 18 countries. Twenty-nine institutions (37%) used TPE for HIT (YES cohort) and 49 (63%) did not (NO cohort). Most NO respondents (65%) cited "no requests received" as the most common reason for not using TPE. Of the 29 YES respondents, 10 (34%) gave incomplete information and were excluded from the final analysis, leaving 19 responses. Of these, 18 (95%) treated ≤10 HIT patients over a 2-year period. The most common indications were cardiovascular surgery (CS; 63%) and HIT-associated thrombosis (HT; 26%). The typical plasma volume processed was 1.0 (63% CS and 58% HT). For CS, the typical replacement fluid was plasma (42%) and for HT, it was determined on an individual basis (32%). For CS, patients were treated with a set number of TPE procedures (37%) or laboratory/clinical response (37%). For HT, the number of TPE procedures typically depended on laboratory/clinical response (42%).
Conclusion: In a minority of responding institutions, TPE is most commonly used in HIT to prophylactically treat patients who will undergo heparin re-exposure during CS. Prospective studies are needed to more clearly define the role of TPE in HIT.
Keywords: heparin-induced thrombocytopenia; practice survey; therapeutic plasma exchange.
© 2019 Wiley Periodicals, Inc.
Conflict of interest statement
DISCLOSURES
The other authors have no relevant conflict of interest to disclose.
Figures
References
-
- Kuter DJ, Konkle BA, Hamza TH, Uhl L, Assmann SF, Kiss JE, Kaufman RM, Key NS, Sachais BS, Hess JR, Ness P, McCrae KR, Leissinger C, Strauss RG, McFarland JG, Neufeld E, Bussel JB, Ortel TL. Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. Am J Hematol 2017;92(8):730–738. - PubMed
-
- Cho JH, Parilla M, Treml A, Wool GD. Plasma exchange for heparin-induced thrombocytopenia in patients on extracorporeal circuits: A challenging case and a survey of the field. J Clin Apher 2018. - PubMed
-
- Iluonakhamhe E, Ibekwe O, Samuel S, Zakaria A. Plasmapheresis may be an option in urgent management of heparin-induced thrombocytopenia in the setting of acute intracerebral hemorrhage. Neurocrit Care 2015;22(1):140–145. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
